Medicine Explained at YOUR Level — From Patient to Physician

Rheumatoid arthritis happens when your immune system
— which normally fights infections — mistakenly attacks
the lining of your joints instead.

Think of it like a security system that malfunctions
and triggers the alarm when there's no intruder. The
alarm (inflammation) causes swelling, pain, and over
time can damage the joint itself.

We don't know exactly why some people's immune systems
do this, but we know:
- It runs in families (genetic component)
- Smoking significantly increases risk
- Women are 3× more likely than men
- It usually starts between ages 30-60

The good news: modern treatments (called DMARDs and
biologics) can stop the damage if caught early. Early
diagnosis and treatment is key.

Questions to ask your doctor:
1. What stage is my RA?
2. Should I start disease-modifying treatment now?
3. What blood tests do I need for monitoring?
4. Should I see a rheumatologist specifically?

RHEUMATOID ARTHRITIS — Board-Relevant Summary

Pathophysiology:
- Autoimmune synovitis: CD4+ T cells activate in
  response to unknown antigen → macrophage recruitment
  → pannus formation → cartilage/bone destruction
- Key cytokines: TNF-α, IL-6, IL-1β (all drug targets)
- Autoantibodies: RF (70% sensitive, not specific),
  Anti-CCP (90% specific, earlier in disease course)
- HLA-DR4 association (shared epitope hypothesis)

Clinical Vignette (USMLE-style):
"A 42-year-old woman presents with 3 months of morning
stiffness lasting >1 hour, symmetric swelling of MCP and
PIP joints bilaterally, sparing the DIPs. Labs show
positive anti-CCP, elevated ESR and CRP."

DDx exercise: What features distinguish this from...
- OA? (DIP involvement, bony enlargement, no morning
  stiffness >30 min, negative RF/CCP)
- SLE? (malar rash, oral ulcers, serositis, ANA+,
  typically non-erosive)
- Psoriatic arthritis? (DIP involvement, dactylitis,
  nail changes, asymmetric pattern)
- Gout? (monoarticular, MSU crystals, tophi, acute onset)

Treatment algorithm:
1st line: Methotrexate (anchor drug)
Add-on if inadequate: TNF inhibitor (adalimumab,
  etanercept) OR IL-6 inhibitor (tocilizumab)
Refractory: JAK inhibitors (tofacitinib), CD20
  depletion (rituximab), T-cell co-stim block
  (abatacept)

High-yield pearl: Anti-CCP can be positive YEARS
before clinical symptoms appear.

RA — Clinical Decision Support

Given presentation, evidence-ranked differential:
1. Rheumatoid arthritis (pre-test probability ~75%
   given symmetric small joint polyarthritis + AM
   stiffness + positive anti-CCP)
2. Viral polyarthritis (Parvo B19, Hep B/C — check
   B19 IgM, hepatitis panel)
3. Early SLE with articular predominance (check ANA,
   dsDNA, complement levels)

Workup priorities:
- Anti-CCP (LR+ = 12.4 if positive, essentially
  diagnostic in this context)
- ESR/CRP (disease activity, not diagnostic)
- Hand/foot X-rays (erosions = late finding, but
  baseline critical)
- Consider US of MCP/PIP joints (synovitis visible
  before clinical swelling, GRADE B evidence)

Treatment initiation (2022 ACR guidelines, GRADE A):
- Methotrexate 15mg/week (NOT low-dose 7.5mg start
  — recent evidence supports moderate starting dose)
- Folic acid 1mg daily (reduces MTX side effects)
- Bridge: prednisone 10mg/day taper over 6-8 weeks
- If MTX intolerant: leflunomide 20mg/day

Monitoring:
- CBC, LFTs, creatinine at baseline, 4 weeks, then
  every 8-12 weeks
- DAS28-CRP every 3 months until remission
- Target: DAS28 < 2.6 (remission) or < 3.2 (low
  disease activity) within 6 months

Red flags for referral:
- RF+ AND anti-CCP+ = high erosive risk → aggressive
  early treatment
- Extra-articular features (nodules, lung, vasculitis)
- Inadequate response at 3 months → biologic discussion

RA — Methodological Considerations for Study Design

Current evidence gaps (publishable research areas):
1. Preclinical RA: Anti-CCP+ asymptomatic individuals
   — what triggers progression? (Prospective cohort
   needed, n>500, 5-year follow-up minimum)
2. Treatment sequencing: After MTX failure, head-to-head
   biologics data is sparse. TNFi vs IL-6i vs JAKi
   comparative effectiveness in real-world data.
3. Biomarker prediction: Multi-omic signatures that
   predict treatment response before drug exposure.

Methodology critique framework for RA trials:
☐ ACR/EULAR 2010 classification criteria used?
☐ DAS28 remission definition (which calculator?
  CRP vs ESR matters — CRP version is less
  influenced by anemia)
☐ Radiographic outcome: modified Sharp score
  (inter-rater reliability reported?)
☐ Patient-reported outcomes included? (HAQ-DI minimum)
☐ Adequate control for confounders: smoking status,
  RF/CCP status, disease duration, prior biologics
☐ Intention-to-treat vs per-protocol (ITT preferred)
☐ Non-inferiority margin justified if NI design?

skills:
  - medicine
  - doctor     # For patient-facing safety
  - pubmed     # For evidence citations